

Jason E Stout

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5601506/publications.pdf>

Version: 2024-02-01

126
papers

4,823
citations

117571

34
h-index

106281

65
g-index

130
all docs

130
docs citations

130
times ranked

5544
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 85-96.	4.6	23
2	Understanding and Communicating Risk: Assessing Both Relative and Absolute Risk Is Absolutely Necessary. <i>JID Innovations</i> , 2022, 2, 100097.	1.2	1
3	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e178-e190.	4.6	51
4	Discordant results of tests for tuberculosis reconsidered – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 164-165.	4.6	0
5	Variability of interferon- γ release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	1
6	COVID-19 Trials: Who Participates and Who Benefits?. <i>Southern Medical Journal</i> , 2022, 115, 256-261.	0.3	2
7	To Boost or Not to Boost Residents and Fellows – That Is the Question. <i>Journal of Graduate Medical Education</i> , 2022, , .	0.6	0
8	Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth – United States, 2012 – 2017. <i>Clinical Infectious Diseases</i> , 2021, 73, e3468-e3475.	2.9	9
9	Tap Water Avoidance Decreases Rates of Hospital-onset Pulmonary Nontuberculous Mycobacteria. <i>Clinical Infectious Diseases</i> , 2021, 73, 524-527.	2.9	15
10	Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 1127-1137.	2.9	23
11	Invasive <i>Mycobacterium abscessus</i> Complex Infection After Cardiac Surgery: Epidemiology, Management, and Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2021, 72, 1232-1240.	2.9	15
12	Social Disadvantage, Politics, and Severe Acute Respiratory Syndrome Coronavirus 2 Trends: A County-level Analysis of United States Data. <i>Clinical Infectious Diseases</i> , 2021, 72, e604-e607.	2.9	11
13	Reduction in Expected Survival Associated With Nontuberculous Mycobacterial Pulmonary Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, e552-e557.	2.9	20
14	Optimising pyrazinamide for the treatment of tuberculosis. <i>European Respiratory Journal</i> , 2021, 58, 2002013.	3.1	15
15	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
16	Environmental risk factors associated with pulmonary isolation of nontuberculous mycobacteria, a population-based study in the southeastern United States. <i>Science of the Total Environment</i> , 2021, 763, 144552.	3.9	10
17	A Cluster of Nontuberculous Mycobacterial Tenosynovitis Following Hurricane Relief Efforts. <i>Clinical Infectious Diseases</i> , 2021, 72, e931-e937.	2.9	7
18	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 598-605.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	2.9	357
20	Universal masking is an effective strategy to flatten the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) healthcare worker epidemiologic curve. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1466-1467.	1.0	59
21	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	3.1	336
22	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	2.9	367
23	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 305-306.	2.5	0
24	Geographic analysis of latent tuberculosis screening: A health system approach. <i>PLoS ONE</i> , 2020, 15, e0242055.	1.1	1
25	877. Use of Statistical Process Control Charts for Early Detection of Healthcare Facility-Associated Nontuberculous Mycobacterial Outbreaks. <i>Open Forum Infectious Diseases</i> , 2020, 7, S475-S476.	0.4	0
26	Molecular Diagnostics for <i>Mycobacterium tuberculosis</i> Infection. <i>Annual Review of Medicine</i> , 2019, 70, 77-90.	5.0	23
27	Papulonecrotic tuberculid and Poncet disease: A case of multisystem delayed-type hypersensitivity in a patient with <i>Mycobacterium tuberculosis</i> infection. <i>JAAD Case Reports</i> , 2019, 5, 794-797.	0.4	5
28	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 381, e23.	13.9	9
29	1386. Reduction in Expected Survival Associated with Nontuberculous Mycobacterial Pulmonary Infection. <i>Open Forum Infectious Diseases</i> , 2019, 6, S503-S504.	0.4	0
30	Application of diagnostic criteria for non-tuberculous mycobacterial disease to a case series of mycobacterial-positive isolates. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 17, 100133.	0.6	4
31	<i>Nocardia</i> infections in the transplanted host. <i>Transplant Infectious Disease</i> , 2018, 20, e12902.	0.7	45
32	Annotated Genome Sequences of 16 Lineage 4 <i>Mycobacterium tuberculosis</i> Strains from Guatemala. <i>Genome Announcements</i> , 2018, 6, .	0.8	2
33	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	3.1	159
34	927. Tap Water Avoidance Decreases Rates of Nontuberculous Mycobacteria in Intensive Care Units. <i>Open Forum Infectious Diseases</i> , 2018, 5, S29-S30.	0.4	4
35	Impact of radiology reports on timely tuberculosis diagnosis. <i>Postgraduate Medical Journal</i> , 2018, 94, 495-498.	0.9	0
36	Evaluating latent tuberculosis infection diagnostics using latent class analysis. <i>Thorax</i> , 2018, 73, 1062-1070.	2.7	36

#	ARTICLE	IF	CITATIONS
37	Corticosteroids for tuberculous pericarditis: can we learn from variability?. International Journal of Tuberculosis and Lung Disease, 2018, 22, 475-475.	0.6	0
38	Health Care Utilization Behaviors Predict Disengagement From HIV Care: A Latent Class Analysis. Open Forum Infectious Diseases, 2018, 5, ofy088.	0.4	8
39	Infection-Induced Vascular Permeability Aids Mycobacterial Growth. Journal of Infectious Diseases, 2017, 215, jiw355.	1.9	46
40	Two-Phase Hospital-Associated Outbreak of <i>Mycobacterium abscessus</i> : Investigation and Mitigation. Clinical Infectious Diseases, 2017, 64, ciw877.	2.9	95
41	Increasing <i>Nocardia</i> Incidence Associated with Bronchiectasis at a Tertiary Care Center. Annals of the American Thoracic Society, 2017, 14, 347-354.	1.5	35
42	A Breath of Fresh Air for Patients with Pulmonary Nontuberculous Mycobacterial Infection. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 716-717.	2.5	0
43	Suboptimal HIV Testing Among Patients Admitted With Pneumonia: A Missed Opportunity. AIDS Education and Prevention, 2017, 29, 377-388.	0.6	8
44	Healthcare Engagement among Persons with HIV: More Than Just Viral Load and Clinic Attendance. Open Forum Infectious Diseases, 2017, 4, S419-S419.	0.4	0
45	Invasive Mycobacterium abscessus Infection after Cardiac Surgery: Epidemiology and Clinical Outcomes. Open Forum Infectious Diseases, 2017, 4, S35-S36.	0.4	0
46	Nocardia infections in the transplanted host. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
47	Incidence and Long-Term Outcomes of Patients With Human Immunodeficiency Virus and Disseminated Mycobacterium avium Complex From 1992 to 2015. Open Forum Infectious Diseases, 2016, 3, .	0.4	2
48	Calculating the economic benefits of what didn't happen. International Journal of Tuberculosis and Lung Disease, 2016, 20, 854-854.	0.6	1
49	Association Between Staff Experience and Effective Tuberculosis Contact Tracing in North Carolina, 2008-2009. North Carolina Medical Journal, 2016, 77, 37-44.	0.1	1
50	Update on pulmonary disease due to non-tuberculous mycobacteria. International Journal of Infectious Diseases, 2016, 45, 123-134.	1.5	267
51	Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes Infection. Immunity, 2016, 45, 861-876.	6.6	176
52	A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Medicine, 2016, 14, 51.	2.3	25
53	Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. International Journal of Tuberculosis and Lung Disease, 2016, 20, 827-831.	0.6	1
54	Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements. International Journal of Tuberculosis and Lung Disease, 2016, 20, 600-604.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Epidemiology of nontuberculous mycobacteria isolations among central North Carolina residents, 2006–2010. <i>Journal of Infection</i> , 2016, 72, 678-686.	1.7	49
56	Getting to a Man's Heart through His Colon. <i>Texas Heart Institute Journal</i> , 2016, 43, 168-170.	0.1	3
57	Mental Health and Substance Use Among Patients in a North Carolina HIV Clinic. <i>North Carolina Medical Journal</i> , 2015, 76, 148-155.	0.1	24
58	Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 333-343.	2.5	102
59	Treating multidrug-resistant tuberculosis in community settings: a wise investment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 127-127.	0.6	1
60	The complexities of Xpert [®] MTB/RIF interpretation. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 273-275.	0.6	9
61	Twenty-eight cases of <i>Mycobacterium marinum</i> infection: retrospective case series and literature review. <i>Infection</i> , 2015, 43, 655-662.	2.3	113
62	The cost of 'free' tuberculosis care. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1413-1413.	0.6	1
63	Whole genome sequencing identifies circulating Beijing-lineage <i>Mycobacterium tuberculosis</i> strains in Guatemala and an associated urban outbreak. <i>Tuberculosis</i> , 2015, 95, 810-816.	0.8	16
64	The Human Antibody Response to the Surface of <i>Mycobacterium tuberculosis</i> . <i>PLoS ONE</i> , 2014, 9, e98938.	1.1	35
65	Integrated Screening for Tuberculosis and HIV in Tuberculosis Contact Investigations: Lessons Learned in North Carolina. <i>Public Health Reports</i> , 2014, 129, 21-25.	1.3	4
66	Advances in the management of pulmonary disease due to <i>Mycobacterium abscessus</i> complex. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1141-1148.	0.6	92
67	Barriers to Using Text Message Appointment Reminders in an HIV Clinic. <i>Telemedicine Journal and E-Health</i> , 2014, 20, 86-89.	1.6	31
68	<i>In Vitro</i> Activity of Amikacin against Isolates of <i>Mycobacterium avium</i> Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1311-1311.	1.8	2
69	Clinical Utility of Indium 111 ^{99m} -Labeled White Blood Cell Scintigraphy for Evaluation of Suspected Infection. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu089.	0.4	23
70	Hepatitis B core antibody ⁺ positive donors in cardiac transplantation: a single-center experience. <i>Transplant Infectious Disease</i> , 2014, 16, 859-863.	0.7	5
71	Community-based HCV screening: knowledge and attitudes in a high risk urban population. <i>BMC Infectious Diseases</i> , 2014, 14, 74.	1.3	45
72	A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania. <i>BMC Infectious Diseases</i> , 2014, 14, 89.	1.3	4

#	ARTICLE	IF	CITATIONS
73	Understanding the costs of better tuberculosis diagnostics. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 508-508.	0.6	0
74	Isoniazid preventive therapy in medium-incidence settings: the price is right. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1388-1388.	0.6	1
75	<i>In Vitro</i> Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3389-3394.	1.8	140
76	Public health costs for tuberculosis suspects in Wake County, North Carolina, United States. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 759-763.	0.6	5
77	The Footprint of Old Syphilis. <i>Sexually Transmitted Diseases</i> , 2013, 40, 839-841.	0.8	3
78	Nontuberculous Mycobacterial Infection after Fractionated CO ₂ Laser Resurfacing. <i>Emerging Infectious Diseases</i> , 2013, 19, 365-70.	2.0	26
79	The race to eliminate tuberculosis. <i>North Carolina Medical Journal</i> , 2013, 74, 415-9.	0.1	0
80	Treatment of <i>Mycobacterium abscessus</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 822-823.	2.5	32
81	Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium. <i>Journal of Infectious Diseases</i> , 2012, 206, 1030-1040.	1.9	98
82	Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. <i>BMC Public Health</i> , 2012, 12, 468.	1.2	43
83	Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis. <i>PLoS ONE</i> , 2012, 7, e30194.	1.1	19
84	Geographic Information System-based Screening for TB, HIV, and Syphilis (GIS-THIS): A Cross-Sectional Study. <i>PLoS ONE</i> , 2012, 7, e46029.	1.1	40
85	Text Messaging for Enhancement of Testing and Treatment for Tuberculosis, Human Immunodeficiency Virus, and Syphilis: A Survey of Attitudes Toward Cellular Phones and Healthcare. <i>Telemedicine Journal and E-Health</i> , 2011, 17, 189-195.	1.6	55
86	Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection. <i>PLoS ONE</i> , 2011, 6, e22276.	1.1	20
87	Did the "Great Recession" produce a depression in tuberculosis incidence? [Short communication]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 700-702.	0.6	10
88	Discriminating between latent and active tuberculosis with multiple biomarker responses. <i>Tuberculosis</i> , 2011, 91, 250-256.	0.8	123
89	Feasibility and willingness-to-pay for integrated community-based tuberculosis testing. <i>BMC Infectious Diseases</i> , 2011, 11, 305.	1.3	9
90	Increased prevalence of advanced tuberculosis in rural low tuberculosis caseload counties in North Carolina. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1455-1461.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Pedicure-Associated Rapidly Growing Mycobacterial Infection: An Endemic Disease. <i>Clinical Infectious Diseases</i> , 2011, 53, 787-792.	2.9	51
92	Pairing QuantiFERON Gold In-Tube with Opt-Out HIV Testing in a Tuberculosis Contact Investigation in the Southeastern United States. <i>AIDS Patient Care and STDs</i> , 2010, 24, 539-543.	1.1	11
93	Treating latent tuberculosis with rifampin: is it the cheaper option?. <i>Thorax</i> , 2010, 65, 572-573.	2.7	3
94	It Is Better to Light a Candle â€¦ Than to Repeat the Opinions of Experts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 865-866.	2.5	5
95	Effect of Improving the Quality of Radiographic Interpretation on the Ability to Predict Pulmonary Tuberculosis Relapse. <i>Academic Radiology</i> , 2010, 17, 157-162.	1.3	11
96	Influence of M. tuberculosis Lineage Variability within a Clinical Trial for Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2010, 5, e10753.	1.1	40
97	HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons. <i>AIDS Patient Care and STDs</i> , 2009, 23, 845-851.	1.1	11
98	Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1055-1060.	2.5	86
99	Therapeutic Drug Monitoring of Antimycobacterial Drugs in Patients with Both Tuberculosis and Advanced Human Immunodeficiency Virus Infection. <i>Pharmacotherapy</i> , 2009, 29, 503-510.	1.2	45
100	Alcohol use and clinical manifestations of tuberculosis. <i>Journal of Infection</i> , 2009, 58, 395-401.	1.7	27
101	Corrigendum to "Alcohol use and clinical manifestations of tuberculosis" [J Infect 57 (2008) 385-391]. <i>Journal of Infection</i> , 2009, 58, 394.	1.7	0
102	Nontuberculous mycobacterial olecranon bursitis: Case reports and literature review. <i>Journal of Shoulder and Elbow Surgery</i> , 2009, 18, e1-e5.	1.2	12
103	Mortality and time to extubation in severe hospital-acquired pneumonia. <i>American Journal of Infection Control</i> , 2009, 37, 143-149.	1.1	9
104	Alcohol use and clinical manifestations of tuberculosis. <i>Journal of Infection</i> , 2008, 57, 385-391.	1.7	17
105	Extrapulmonary tuberculosis, human immunodeficiency virus, and foreign birth in North Carolina, 1993 â€“ 2006. <i>BMC Public Health</i> , 2008, 8, 107.	1.2	35
106	Cavitary Pulmonary Disease. <i>Clinical Microbiology Reviews</i> , 2008, 21, 305-333.	5.7	299
107	Association between 16S-23S Internal Transcribed Spacer Sequence Groups of <i>Mycobacterium avium</i> Complex and Pulmonary Disease. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2790-2793.	1.8	20
108	Predicting Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1055-1057.	2.5	20

#	ARTICLE	IF	CITATIONS
109	Tuberculosis knowledge, attitudes, and beliefs among North Carolinians at increased risk of infection. <i>North Carolina Medical Journal</i> , 2008, 69, 14-20.	0.1	26
110	Extensively Drug-Resistant Tuberculosis: Are We Learning from History or Repeating It?. <i>Clinical Infectious Diseases</i> , 2007, 45, 338-342.	2.9	32
111	Pharmacokinetics of Rifampicin. <i>Clinical Infectious Diseases</i> , 2007, 44, 618-619.	2.9	8
112	Central Nervous System Infection and Cutaneous Lymphadenitis Due to <i>Mycobacterium kansasii</i> in an Immunocompetent Patient. <i>Infection</i> , 2007, 35, 291-294.	2.3	5
113	Evaluation and management of patients with pulmonary nontuberculous mycobacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 981-993.	2.0	14
114	Inhaled Azithromycin Therapy. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2006, 19, 54-60.	1.2	35
115	Racial and Ethnic Disparities in Pediatric Tuberculosis in North Carolina. <i>JAMA Pediatrics</i> , 2006, 160, 631.	3.6	25
116	Risk Factors for Ineffective Therapy in Patients With Bloodstream Infection. <i>Archives of Internal Medicine</i> , 2005, 165, 308.	4.3	69
117	Current issues in global tuberculosis control. <i>International Journal of Infectious Diseases</i> , 2005, 9, 297-311.	1.5	39
118	Tuberculosis Transmission from a Patient with Skin Lesions and a Negative Sputum Smear. <i>New England Journal of Medicine</i> , 2004, 350, 2527-2528.	13.9	2
119	Risk Factors for Infective Endocarditis in Patients with Enterococcal Bacteremia: A Case-Control Study. <i>Infection</i> , 2004, 32, 72-77.	2.3	68
120	Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 187-198.	1.0	6
121	Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 187-198.	1.0	2
122	Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 824-827.	2.5	74
123	Reactivation of Retinal Toxoplasmosis Despite Evidence of Immune Response to Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2002, 35, e37-e39.	2.9	13
124	Epidemiology of Human Immunodeficiency Virus Testing Among Patients With Tuberculosis in North Carolina. <i>Southern Medical Journal</i> , 2002, 95, 231-238.	0.3	8
125	Epidemiology of human immunodeficiency virus testing among patients with tuberculosis in North Carolina. <i>Southern Medical Journal</i> , 2002, 95, 231-8.	0.3	7
126	Hospital Management of Tuberculosis in a Region With a Low Incidence of Tuberculosis and a High Prevalence of Nontuberculous Mycobacteria. <i>Infection Control and Hospital Epidemiology</i> , 2001, 22, 715-717.	1.0	1